Clinical trials: Hnscc
HNSCC, Melanoma
Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors
The subject of this study is the adoptive transfer of selected autologous tumor infiltrating lymphocytes (TIL) after in vitro expansion for the treatment of solid tumor malignancies.
- Conditions
- HNSCC, Melanoma, Gynecologic Cancer, Colorectal Cancer
- Trial name
- ACT (NCT05902520)
- Testing
- DP CD8 TIL, DP CD8 TIL KD, Low dose IL-2
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- AgonOx, Inc.
Squamous Cell Carcinoma of the Head and Neck, Melanoma
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced…
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NCT03894618
- Testing
- SL-279252
- Where
- 5 sites in United States, Belgium and 2 more
- Volunteers
- 49 people
- Sponsor
- Shattuck Labs, Inc.
Head and Neck Cancer
Liposomal Lurtotecan in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of liposomal lurtotecan in treating patients who have…
- Trial name
- NCT00022594
- Testing
- liposomal lurtotecan
- Where
- 20 sites in Austria, Belgium and 8 more
- Volunteers
- 50 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cancer, Solid Tumor
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab [Gazyva®] pre-treatment, by IV infusion, and in…
- Conditions
- Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma
- Trial name
- NCT04787042
- Testing
- ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 316 people
- Sponsor
- Simcha IL-18, Inc.
Head and Neck Cancer
Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00833261
- Testing
- cetuximab, cisplatin, intensity-modulated radiation therapy
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- University of Texas Southwestern Medical Center
Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer, Squamous Cell Carcinoma of the Lung
- Trial name
- NCT04429542
- Testing
- BCA101, Pembrolizumab
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 473 people
- Sponsor
- Bicara Therapeutics
HNSCC, Head and Neck Neoplasms
Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma
Phase II study of Durvalumab+/- Tremelimumab in patients with recurred metastatic head and neck squamous cell carcinoma
- Trial name
- NCT06446570
- Testing
- Durvalumab,Tremelimumab
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- Seoul National University Hospital
Fanconi Anemia, Head and Neck Squamous Cell Carcinoma
Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
This research study is a phase Ib/II, single-arm, non-randomized, non-blind, multicenter study designed to determine whether Afatinib is effective and safe in patients with locoregionally unresectable and / or metastatic HNSCC…
- Trial name
- AFAN (NCT06648096)
- Testing
- Afatinib
- Where
- 2 sites in Germany, Spain
- Volunteers
- 25 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer
A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation
This is a phase II, single center, open label, multi-cohort platform study to identify a signature in tumor tissues, blood or stool that might help identify participants who are more likely to experience tumor shrinkage or side…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- DOME (NCT04262388)
- Testing
- Durvalumab, Oleclumab
- Where
- Canada
- Sponsor
- University Health Network, Toronto
Non-small Cell Lung Cancer, Colorectal Cancer
A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China
This is a Phase 1, open-label dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and assess the DLT of JAB-3312.
- Conditions
- Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04121286
- Testing
- JAB-3312
- Where
- 5 sites in China
- Volunteers
- 17 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Advanced Solid Tumor, CDKN2A
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
This is an open-label, single-arm, Phase 1b/2 study designed to evaluate the safety, tolerability, and preliminary efficacy of milademetan in combination with atezolizumab in patients with advanced solid tumors with confirmed…
- Conditions
- Advanced Solid Tumor, CDKN2A, NSCLC, Urothelial Carcinoma Bladder
- Trial name
- NCT06090318
- Testing
- Milademetan, Atezolizumab
- Sponsor
- Rain Oncology Inc
Head and Neck Squamous Cell Carcinoma
Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT
This study compare the survival without laryngeal dysfunction 2 years after the end of treatment, obtained by chemotherapy followed by radiotherapy or chemotherapy with cisplatin administrated during radiotherapy.
- Trial name
- SALTORL (NCT03340896)
- Testing
- Docetaxel, Cisplatin, Fluorouracil
- Where
- France
- Volunteers
- 256 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Squamous Cell Carcinoma of Head and Neck
Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck
This study will test the ability of a personalized blood test to determine which head and neck cancer patients will have a recurrence after treatment.
- Trial name
- MRD-DUCHESS (NCT06744296)
- Testing
- Blood Draws and Tissue Sample(s)
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Non-Small Cell Lung Carcinoma (NSCLC), Metastatic Head and Neck Squamous Cell Carcinoma
Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy.
This is a single-center pharmacokinetic study evaluating the impact of residual pembrolizumab levels on the efficacy of salvage chemotherapy following immunotherapy in patients with non-small cell lung cancer (NSCLC) or recurrent…
- Trial name
- CPI (NCT07633613)
- Testing
- Blood sampling, Tumor biopsies for biobank establishment (optional)
- Volunteers
- 110 people
- Sponsor
- Centre Antoine Lacassagne
Advanced Solid Tumors Cancer
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when…
- Trial name
- NCT02988960
- Testing
- ABBV-927, ABBV-181
- Where
- 22 sites in United States, Australia and 5 more
- Volunteers
- 163 people
- Sponsor
- AbbVie
Head and Neck Cancer
A Study of the Intratumoural Administration of CAVATAK to Head and Neck Cancer Patients (VLA-X06)
This study is designed to assess the safety and initial indications of efficacy resulting from multiple doses of CAVATAK injected directly into solid tumours of the Head and Neck that have been confirmed to express ICAM-1 and…
- Trial name
- VLA-X06 (NCT00832559)
- Testing
- CVA21
- Where
- 3 sites in Australia
- Volunteers
- 4 people
- Sponsor
- Viralytics
Carcinoma, Squamous Cell of Head and Neck, Gastric Adenocarcinoma
A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer
Patients in the Phase 1b part of the study will be treated with ilixadencel at an increasing dose and frequency, in combination with standard doses and schedules of checkpoint inhibitor (CPI) pembrolizumab.
- Conditions
- Carcinoma, Squamous Cell of Head and Neck, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Non-small Cell Lung Cancer
- Trial name
- ILIAD (NCT03735290)
- Testing
- ilixadencel, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Mendus
Squamous Cell Carcinoma of the Head and Neck, Carcinoma, Squamous Cell of the Head and Neck
Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)
In this trial, the objectives are to determine the efficacy and toxicity of induction chemotherapy (IC) with nab-paclitaxel + cisplatin (Arm 1: AP) and with nab-paclitaxel (Arm 2: A) alone in patients with HNSCC, and to compare…
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Carcinoma, Squamous Cell of the Head and Neck, Cancer of Head and Neck, Cancer of the Head and Neck
- Trial name
- APA (NCT02573493)
- Testing
- nab-Paclitaxel, Cisplatin, Cetuximab
- Where
- 3 sites in United States
- Volunteers
- 96 people
- Sponsor
- Washington University School of Medicine
Advanced Malignancies, Metastatic Cancer
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
- Trial name
- NCT03277352
- Testing
- INCAGN01876, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Biosciences International Sàrl
Squamous Cell Carcinoma of the Head and Neck
Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC
This is an open label pilot study evaluating the pharmacodynamics and safety of single agent olaparib administered at 300mg bid (twice a day) for 14 days orally in patients with human papillomavirus (HPV) -positive and human…
- Trial name
- NCT02686008
- Testing
- Olaparib
- Sponsor
- Yale University